SpringWorks Therapeutics Inc. upsized an IPO of its shares on Nasdaq and is now looking to sell 9 million shares.
The Connecticut-based biopharmaceutical company was previously looking to sell 7,352,941 shares. The IPO's price range still remains at between $16 per share and $18 per share.
Goldman Sachs & Co. LLC, Wedbush PacGrow, J.P. Morgan Securities LLC and Cowen and Co. LLC are the underwriters of the IPO and will have an option to buy up to an additional 1,350,000 shares.
SpringWorks Therapeutics plans to use the proceeds to further the clinical development of its drugs nirogacestat and mirdametinib, among other things.
